Pain Resource Community
aweber posted in the group Diabetes
In April, Eliem Therapeutics’ lead candidate, ETX-810, failed a Phase II study for diabetic nerve pain
Dang, that is a bummer.
[youzify_profile_completeness]
Dang, that is a bummer.